Medicinal Chemistry
The Modern Drug Discovery Process

Erland Stevens
Davidson College, North Carolina
Contents

Acknowledgments xiii

Chapter 1

A Brief History of Drug Discovery 1

1.1 Selected Drugs from Early Recorded History 1
  China 2
  India 2
  Middle East 2
  Greek, Roman, and Byzantine Periods 3

1.2 Middle Ages to Modern Times 3
  Natural Products 4
  Advances in Inorganic Chemistry 5
  Sulfur Drugs 7

1.3 Evolution of the U.S. Food and Drug Administration 8
  Corporate Self-Regulation 8
  Food, Drug, and Cosmetic Act of 1938 9
  Continuing Challenges and Refinements 9

Summary 12 • References 12

Chapter 2

The Modern Drug Discovery Process 13

2.1 Market Analysis 13

Case Study Treatment of Acid Reflux 14

2.2 Target Selection 15
  Finding a Target 15
  Traditional Methods 16

Case Study ACE Inhibitors and A-II Receptor Blockers 16

Case Study HMG-CoA Reductase Inhibitors 18
  Assay Development 20

2.3 Lead Discovery 24

2.4 Lead Optimization 24

2.5 Patent Filing 25

2.6 Animal Trials 25

2.7 Investigational New Drug Application 26

2.8 Phase Trials 26
  Phase I 26
  Phase II 26
  Phase III 27

2.9 New Drug Application 28

2.10 Launch 28
Chapter 3

A Trip through the Body 34

3.1 The Complexity of the Body 34

What Is the Body? 34
Organization of the Body 35
Balance of Life 37

3.2 Absorption: Drug Entry into the Bloodstream 38

Oral 38
Injection 42
Transdermal 44
Other Routes 44
Topical 46

3.3 Distribution: Drug Transport 47

Blood 47
Crossing Membranes 49
Blood–Brain Barrier 55

3.4 Pharmacodynamics: At the Drug Target 55

3.5 Metabolism and Elimination: Drug Removal 56

KIDneys 56
Liver 58
Other Routes 59

Summary 59 • Questions 60 • References 61

Chapter 4

Enzymes as Drug Targets 62

4.1 Introduction to Enzymes 62

Definition 62
Structure 64

Case Study Use of α-Helices to Cross Cell Membranes 67

Types 69

4.2 Mode of Action 70

Theory 70
Regulation 71

4.3 Kinetics 72

Single Substrate 72
Multiple Substrates 78

4.4 Inhibitors 79

Reversible 79
Irreversible 84
### Chapter 5

**Receptors as Drug Targets**

5.1 Receptors 94
- Similarities to Enzymes 94
- Differences from Enzymes 95

5.2 Receptor Classification 95
- Ligand-Gated Ion Channels 96
- G-Protein–Coupled Receptors 97
- Tyrosine Kinase–Linked Receptors 99
- Nuclear Receptors 100

5.3 Types of Ligands 100
- Agonists 101
- Antagonists 104
- Inverse Agonists 106

5.4 Receptor Theories 107
- Occupancy Theory 107
- Allosteric Theory 115
- Rate Theory 116
- Drug-Target Residence Time 117

**Summary** 119  •  **Questions** 119  •  **References** 120

### Chapter 6

**Oligonucleotides as Drug Targets** 122

6.1 The Basics of Nucleic Acids 122
- The Building Blocks of Nucleic Acids 122
- DNA 125
- RNA 126

6.2 Common Methods of Oligonucleotide Recognition 130
- Base Pairing 130
- Charge-Charge Interactions 133
- Intercalation 133
- Groove Binding 136

6.3 Interference with Nucleic Acid Synthesis and Function 139
- Anti-HIV Nucleic Acid Analogues 139
- Nucleic Acid Antimetabolites 142
- Tubulin Interactions 144

**Summary** 145  •  **Questions** 145  •  **References** 148
Chapter 7

Pharmacokinetics 150

7.1 Intravenous Bolus 150
   \( C_p \) vs. Time and Elimination 150
   Clearance 155
   Volume of Distribution 159
   Serum Binding 165

   Case Study Minimization of Serum Binding 166

7.2 Intravenous Infusion 167
   Infusion Rate Constant 167
   Loading Bolus 169
   Infusion-Like Administration Routes 171

7.3 Oral 172
   Absorption and Elimination Phases 172
   Bioavailability 173
   Absorption Rate Constant 174
   Multiple Oral Doses 176
   Clearance and Volume of Distribution Revisited 178

   Case Study Fast Onset Sertraline Analogues 180

7.4 Drug Metabolites 181

Summary 182 • Questions 182 • References 184

Chapter 8

Metabolism 185

8.1 Introduction 185

8.2 Metabolic Reactions 186
   Phase I Reactions 186
   Phase II Reactions 193

8.3 Metabolism Issues 197
   Metabolite Activity 197

   Case Study Sertraline and Later Generation SSRIs 198

   Case Study Acetaminophen 201

   Case Study MPPP 202
     Inhibition of Metabolism by Drugs 203

   Case Study Cimetidine 204

   Case Study St. John’s Wort 204
     Population Variations 205

   Case Study Theophylline 206

8.4 Prodrugs 208
   Case Study Clopidogrel and Prasugrel 209

Summary 211 • Questions 211 • References 212
Chapter 9  
**Molecular Structure and Diversity** 214
9.1 Determining Target Structure 214
   - Literature 215
   - X-Ray Crystallography 215
   - NMR Spectroscopy 217
   - Molecular Modeling 217
   **Case Study** Protease Inhibition in Coronaviruses 218
9.2 Complementarity between a Target and Drug 220
   - Intermolecular Forces 220
   - Molecular Shape 225
   **Case Study** Conformational and Stereochemical Effects on Ligands of Acetylcholine Receptors 225
   - Drug Pharmacophore 228
9.3 Searching for Drugs 228
   - Diversity and Molecular Space 228
   - Privileged Structures 230
9.4 Combinatorial Chemistry 231
   - Parallel Synthesis 232
   - Split Synthesis 237
   - Advantages and Disadvantages 240
**Summary** 242 • **Questions** 243 • **References** 245

Chapter 10  
**Lead Discovery** 247
10.1 Approaches to Searching for Hits 247
   - Traditional Library Screening 247
   - Fragment-Based Screening 251
   **Case Study** Inhibition of Stromelysin 252
   **Case Study** Inhibition of Cyclin-Dependent Kinase 2 254
   **Case Study** Inhibition of Acetylcholine Esterase 255
   Virtual Screening 257
   **Case Study** Inhibition of Protein Kinase B 257
   **Case Study** Inhibition of Sir2 Type 2 258
   **Case Study** C–C Chemokine Receptor Type 5 Agonists 259
10.2 Filtering Hits to Leads 260
   - Pharmacodynamics and Pharmacokinetics 260
   - Biological Assays 261
   - Lipinski’s Rules and Related Indices 261
   - Final Concerns for Promotion of a Hit to a Lead 263
10.3 Special Cases 264
   - Serendipity 264
   **Case Study** Penicillin 264
   **Case Study** Chlordiazepoxide 265
   Clinical Observations 265
   **Case Study** Viloxazine 266
Chapter 11

Lead Optimization: Traditional Methods  273

11.1 Pharmacophore Determination  273
  
  Case Study The Pharmacophore of Morphine  274
  
  Case Study The Pharmacophore of Migrastatin, a Promising Anticancer Compound  274

11.2 Functional Group Replacements  275

11.3 Alkyl Group Manipulation  278
  
  Chain Homologation  278
  
  Ring-Chain Interconversion  279

11.4 Isosteres  279
  
  Case Study Cimetidine  283

11.5 Directed Combinatorial Libraries  287
  
  Case Study Raf Kinase Inhibitors  288

11.6 Peptidomimetics  288
  
  Case Study Angiotensin-Converting Enzyme Inhibitors  290
  
  Case Study Human Immunodeficiency Virus-1 Protease Inhibitors  292

Summary  294  •  Questions  294  •  References  296

Chapter 12

Lead Optimization: Hansch Analysis  298

12.1 Background  298

12.2 Parameters  299
  
  Hammett Constants: An Electronic Parameter  300
  
  Hansch Constants: A Lipophilicity Parameter  302
  
  Taft Steric Parameter  305
  
  Other Parameters  306

12.3 Hansch Equations  307
  
  Case Study Phosphonate Ester Cholinesterase Inhibitors  308
  
  Case Study Carboxylate Antifungals  310
  
  Case Study Tumor Cell Resistance Modulators  311

12.4 Craig Plots  313

12.5 Topliss Trees  314

12.6 Evaluating Hansch Analysis  314

12.7 Comparative Molecular Field Analysis  315
  
  Case Study Comparing Hansch Analysis and CoMFA  316

Summary  317  •  Questions  318  •  References  319

Chapter 13

Aspects in Pharmaceutical Synthesis  321

13.1 Solids, Solids, Solids  321
  
  Recrystallization  322
  
  Acid–Base Salts  323